Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

PHASE3CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 27, 2018

Study Completion Date

December 27, 2018

Conditions
Severe Hemophilia A
Interventions
BIOLOGICAL

Human-cl rhFVIII

Trial Locations (15)

95817

UC Davis Medical Center, Sacramento

411004

Sahyadri Speciality Hospital, Pune

632004

Christian Medical College, Vellore

Unknown

University of Alberta, Edmonton

Hospital for Sick Children, Toronto

Hopital de la Timone, Marseille

Hôpital Kremlin Bicètre, Paris

Institute of Hematology and Transfusiology, Tbilisi

IMSP Mother and Child Institute, Chisinau

University Medical School, Warsaw

"The National Children Specialized Hospital OHMATDET", Kiev

Danylo Halytsky Lviv National Medical University, Lviv

V6H 3V4

BC Children's Hospital, Vancouver

L8S4K1

McMaster Children's Hospital, Hamilton

WC1N 3JH

Great Ormond Street Hospital for Children, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Octapharma

INDUSTRY